IQE plc

Overview

This is a deep value analysis of IQE plc (LSE:IQE) – a hated, dismissed, and deeply misunderstood compound semiconductor wafer manufacturer that has become a battleground between institutional bears and retail believers. The stock traded as low as 4.66p in its 52‑week range, and after a huge surge driven by an AI photonics re‑rating, a MACOM‑led £81m investment, and a strategic review, it now sits at 38p. The market still prices IQE as a broken foundry, but the fundamentals are shifting beneath the surface. This report applies the Keith Gill methodology – digging into the financials, the narrative, and the extreme sentiment that creates asymmetric upside when everyone is looking the wrong way.

The Bear Case

Wall Street sees a serial disappointer: IQE has negative earnings, zero gross margins, years of cash burn, a customer‑concentration problem with Apple, and a history of dilutive placings. The bears argue the company is a structurally challenged, commoditised epiwafer supplier with no pricing power. The recent run from 5p to 73p is called a speculative meme‑driven bubble that has already popped, and the pullback to 38p proves the sceptics right. Analysts downgraded the stock after the MACOM deal, warning that the business still needs to prove it can generate consistent cash flow. Simply Wall St flags significant insider selling, and the credit analysis sites describe a ‘subordinated debt trap’ and a ‘binary bet on survival’. In short, the consensus is that IQE is an execution‑risk disaster that will keep disappointing.

The Bull Case

The crowd is missing the forest for the trees. IQE is the world’s largest independent manufacturer of compound semiconductor epitaxial wafers – the essential material layer for every high‑performance laser, RF amplifier, and power transistor in the AI, defence, and 5G supply chains. The AI datacentre build‑out is fuelling a photonics super‑cycle, and IQE is the only Western foundry at scale that can grow the InP and GaAs epiwafers needed for 800G/1.6T optical interconnects. Lumentum extended a multi‑year supply agreement. MACOM, a tier‑one semiconductor company, just put £30m of fresh equity into IQE and signed long‑term supply agreements – that is not the behaviour of a company betting on failure. The balance sheet has been transformed: after the £81m fundraise, IQE moved to a net cash position and killed the strategic‑review overhang. Revenue is recovering, and with improved factory utilisation, gross margins are set to inflect sharply. The stock may have pulled back, but the weighted probability‑based fair value, using conservative scenarios, still points to £0.62–£1.55 per share (USD), implying material upside from the current £0.38 level. The bears are anchored to the old, distressed narrative, while the business has already turned the corner.

Fundamental Deep Dive

Sentiment & Technical Setup

Catalyst Analysis

The next major catalyst is the FY2025 earnings release (expected around September 2025, but the financial data references a date window). More immediately, any update on Q2‑2026 trading could show continued revenue acceleration and gross margin improvement. The newly formed MACOM supply agreements will start ramping, and the company can now invest in InP and GaN capacity having resolved its balance‑sheet crisis. A potential US listing or a takeover bid from a defence prime or photonics integrator remains on the table – the strategic asset value is undeniable now that IQE is no longer a distressed seller. The broader AI/data‑centre capex cycle is still in its early innings, and each hyperscaler earnings call that highlights optical interconnect demand is a catalyst. Finally, the sheer technical setup – a pullback to 38p from a high of 73p – creates a coiled spring for the next leg up if sentiment flips.

Key Risks

Conclusion

The market is still pricing IQE like a distressed cyclical, but the company has moved beyond mere survival. The combination of a repaired balance sheet, strategic supply agreements with tier‑one photonics players, and exposure to the fastest‑growing segment of the semiconductor industry (AI optical interconnects) is not being fully reflected in a £372m market cap. The bear narrative of chronic losses and dilution is stale; the company has just been recapitalised and is entering a revenue upswing. While volatility will remain extreme, and the risk of a ‘dead cat bounce’ is real, the asymmetry is clear: if IQE can sustain even a moderate recovery, the stock can easily re‑rate to 60‑80p. The deep value play requires patience, but the setup is exactly the kind of hated, misunderstood, and heavily shorted situation that can produce outsized returns when the narrative finally flips.

Overview

A Peter Lynch-style analysis of IQE plc (LSE:IQE), a UK-listed compound semiconductor wafer maker, using the principles of 'invest in what you know', stock categorization, and seeking tenbaggers. The report assesses IQE's turnaround potential amid AI and defense tailwinds, insider selling concerns, and recent strategic investments.

The Two-Minute Story

IQE makes the ultrapure, ultraflat wafers that go into lasers, 5G phone chips, and facial recognition sensors. Think of them as the invisible 'raw material' for advanced chips that can't be made from silicon. After two terrible years where phone demand slumped and inventories piled up, three things changed: AI data centers started guzzling optical interconnects that need IQE's indium phosphide wafers, US defense spending on radar and sensing jumped, and a big customer, MACOM, invested £81 million, wiping out debt and giving them breathing room. The company is still losing money, but revenues are turning up, the order book is strong, and if they can convert just 10% of revenues into profit, you could see a dramatic swing from loss to profit. It's an ugly duckling with a few tailwinds at its back.

Stock Category

Do You Understand This Business?

IQE's business is complex – it grows atom-thin layers of exotic materials like gallium arsenide and indium phosphide on wafers. But the consumer end is easy: these wafers enable the Face ID on iPhones, 5G signal amplifiers, and the laser links inside AI data centers. An average person can understand 'they make the stuff that makes your phone's face unlock work and your 5G fast.' The edge comes from recognizing that the industry is cyclical but has high barriers to entry (years of customer qualification, proprietary recipes). If you follow the news on AI infrastructure building and defense spending, you can see demand coming before IQE's reported results reflect it.

PEG Ratio Analysis

Lynch's Checklist

Tenbagger Potential

From 38p, a tenbagger would reach 380p, implying a market cap of £3.72 billion. This is ambitious but not impossible if several things happen: (1) Revenue grows to £300-400 million, driven by AI photonics and GaN power. (2) Gross margins recover from near zero to 20-25%. (3) The company achieves consistent free cash flow and re-rates to a 15-20x P/E. (4) No further massive dilution. However, the probability is low; the company has a history of value destruction and share dilution. A more realistic bull case might see a 3-5x return if the turnaround delivers, but a tenbagger likely requires a sustained technology super-cycle that IQE leads. Lynch would say, 'Tenbagger? Only if everything breaks right, and even then, I'd want a lot of evidence first.'

Key Risks

Conclusion

Peter Lynch would find IQE fascinating but frustrating. It's a boring, overlooked business with a moat (qualifications, know-how), riding huge secular trends. However, Lynch's key signs for buying a turnaround are a healthy balance sheet, insider buying, and improving same-store sales/earnings. IQE just fixed the balance sheet (good), but we see insider selling (bad) and no positive earnings yet (bad). Lynch would likely want to see at least one or two quarters of actual earnings growth before committing, to avoid catching a falling knife in a cyclical downturn. For now, the stock is a 'hold' – you don't sell if you bought at the bottom, but you don't add new money until management shows they can convert the AI/defense tailwinds into real profits, and insiders start putting their own cash back in. The story makes sense in two minutes, but the evidence of a real turnaround is still incomplete.

Overview

A Druckenmiller-style macro-driven assessment of IQE plc, a compound semiconductor epitaxial wafer foundry at the epicentre of the AI photonics, defence, and power electronics mega-trends. The analysis evaluates the cyclical trough, reflexive recovery dynamics, strategic balance-sheet repair, and asymmetric upside against persistent execution risks.

Macro Context

The global economy in mid-2026 is navigating a late-cycle expansion with moderating inflation and a central bank pivot towards easing—providing a supportive backdrop for capital-intensive technology investments. A secular AI infrastructure super-cycle is driving hundreds of billions in hyperscale data-centre capex, creating unprecedented demand for high-speed optical interconnects. Simultaneously, heightened geopolitical tension is fuelling a multi-year defence spending up-cycle in NATO countries, while 5G/6G rollout and vehicle electrification sustain structural demand for compound semiconductors. These forces converge on the critical photonics and RF supply chain, where Western governments are increasingly keen to secure domestic manufacturing capabilities.

Company Position in Macro Landscape

IQE sits at the foundational layer of this macro mosaic. As the world’s largest independent compound semiconductor epiwafer foundry, it supplies the essential InP, GaAs, and GaN wafers that enable 800G/1.6T optical transceivers, mmWave 5G power amplifiers, phased-array radar, and GaN power ICs. It is a direct beneficiary of the AI data-centre buildout, the defence modernisation wave, and the electrification trend. The company’s Cardiff-based, Western-centric manufacturing footprint further aligns with the de-risking of semiconductor supply chains. After a brutal cyclical inventory correction in 2024/2025, IQE has emerged from its trough with a repaired balance sheet, a strategic long-term supply agreement with MACOM, and a validated technology position reinforced by Nvidia’s $2bn investment in the photonics ecosystem (Lumentum/Coherent). It is a classic cyclical turnaround with secular tailwinds.

Reflexivity Analysis

IQE is currently in a powerful positive-feedback loop that was utterly absent twelve months ago. The initial catalyst—the MACOM-led £81m fundraise and the conclusion of the strategic review—eliminated the existential liquidity fear. This has triggered a self-reinforcing process: (1) a fortified balance sheet restores customer and supplier confidence, enabling long-term supply agreements; (2) those agreements provide revenue visibility, allowing management to optimise capacity utilisation; (3) rising utilisation drives gross-margin recovery, moving the P&L towards breakeven; (4) improving financials and the AI photonics narrative attract institutional interest, repricing the shares upwards; (5) a higher equity valuation further reduces perceived risk, potentially opening doors to a US listing or strategic M&A at a premium. Critically, short interest has collapsed (down 85%), removing the negative reflexivity of forced covering rallies. The risk is that this reflexive loop runs in reverse if execution falters—revenue misses would quickly reverse sentiment, given the low margin of safety on current profitability. For now, the momentum is aligned with fundamentals improving at the margin.

Competitive Position & Disruptive Threats

IQE’s moat lies in three decades of epitaxial process know-how, a vast portfolio of qualified customer recipes, and high switching costs (12–24 month requalification cycles). The MACOM strategic partnership cements its position in key growth segments (InP, GaN) and effectively locks in a tier-one customer for the long term. The company’s IP portfolio—including VCSEL, Micro LED, and cREO technologies—provides optionality on next-generation AR/VR and silicon photonics. However, the competitive landscape is not benign. Vertically integrated IDMs like Coherent and Wolfspeed, and well-funded Chinese foundries, threaten to capture value further up the stack or in lower-cost markets. The primary threat is not technological obsolescence but business-model erosion: if hyperscalers and module makers aggressively integrate epitaxial growth in-house, IQE’s addressable market could shrink. For the next 2–3 years, supply constraints and capacity shortages across the compound semiconductor industry mitigate this risk; IQE’s independence becomes an asset, not a liability, as customers scramble for qualified wafer supply.

Asymmetric Risk/Reward

At 38 GBp and a market cap of ~£372m, IQE offers a convex payoff. The downside is partly cushioned by the 19.8p fundraising floor and the tangible asset base; a worst-case bear scenario of zero revenue recovery and renewed distress could see the stock fall to 15–20 GBp (c.50% downside). The upside, however, is multi-fold: base-case revenue recovery to £150–160m with a return to positive gross margins could support a 60–70 GBp share price (c.80% upside). A bull-case scenario of >£200m revenue and 20%+ gross margins, driven by full photonics supercycle participation, would justify a 100–150 GBp valuation (2–4x current price). The MACOM deal, Lumentum multi-year agreement, and Nvidia’s indirect endorsement provide hidden optionality—a strategic acquirer (US defence prime, photonics integrator) might pay a significant control premium. The risk/reward is clearly skewed to the upside for a patient investor willing to tolerate quarterly volatility.

Key Risks

Investment Details

Overview

This is a Magic Formula-style analysis of IQE plc (IQE.L), a UK-based compound semiconductor wafer manufacturer. The analysis evaluates whether the stock qualifies as a 'good business at a bargain price' using Joel Greenblatt's criteria of high earnings yield and high return on capital. Given the available financial data, the company currently fails both quantitative screens due to negative EBIT and low/negative ROC, making it unattractive for a systematic Magic Formula portfolio. However, the report explores whether normalized earnings might present a contrarian case.

Business Quality Assessment

IQE is a cyclical, capital-intensive foundry for epitaxial wafers used in photonics, wireless, and power electronics. Historically, the business has struggled to convert its technical moat—complex MOCVD epitaxy processes with high switching costs—into consistent profitability. Over the past five years, earnings have declined by 18.4% annually, and the trailing twelve months show negative gross margins (~0%) and a net loss of £49.14 million on £97.27 million revenue. Return on capital (EBIT / (NWC + NFA)) is negative because EBIT is deeply negative while the asset base (manufacturing facilities) is substantial. Even in better years, adjusted ROC appears low; the business lacks the durable competitive advantage and pricing power required for a high-ROC Magic Formula stock. The current focus on AI photonics, GaN power, and defense markets offers secular growth tailwinds, but IQE has yet to demonstrate it can sustainably earn above its cost of capital. In Greenblatt's framework, this is not a 'good' business.

Valuation Analysis

As of the latest data (price 38 GBp, market cap £372 million), the stock trades at a massive premium to its current earnings power. TTM EBIT is negative, so earnings yield is negative—there is no cheapness. Enterprise value (with roughly £50-70 million net debt pre-MACOM deal) likely exceeds £400 million against TTM revenue of £97 million and adjusted EBITDA of just £2 million. Even on a normalized basis, if we generously assume £8-10 million EBIT in a recovery year (based on historical adjusted EBITDA of £8.1 million in 2024 less D&A), the earnings yield would be only ~2-2.5%, far below the UK 10-year gilt yield and other equity alternatives. The stock is not cheap; it is priced for a dramatic turnaround or a takeover premium. From a Magic Formula perspective, it would rank near the bottom on earnings yield.

Magic Formula Ranking

Normalized Earnings Analysis

Current TTM earnings are depressed by a severe cyclical downturn: revenue fell 31% in H1 2025 due to wireless inventory destocking and delayed defense funding. Management guided to improving momentum into 2026. A normalized picture might assume revenue returning to £120-130 million and adjusted EBITDA of £10-12 million, with EBIT low-single-digit positive after D&A. However, IQE's history of profitability is patchy: even in good years, operating margins rarely exceeded 5-8%, and free cash flow has been elusive due to ongoing capex. One-time items include impairment charges (£7.6m in H1 2025) and restructuring costs. Adjusting for these, sustainable owner earnings might be £5-8 million on a run-rate basis—still a tiny yield on the current enterprise value. Thus, normalized earnings fail to support the current valuation.

Why The Market Is Wrong

The market may be dismissing IQE's potential as a critical supplier in AI photonics (InP lasers, VCSELs for data centers) and GaN power, as well as defense applications. The company has secured multi-year supply agreements with Lumentum and Qualcomm, and the MACOM strategic investment validates its technology. The market's 'concern'—that IQE is a structurally unprofitable cyclical—could be overdone if the company successfully transitions to higher-margin photonics and power markets, driving both revenue growth and margin expansion. The contrarian case is that current losses are temporary, and a few large customer wins could transform the earnings profile, making the stock a deep value play in hindsight. However, this requires substantial execution risk and a belief that the cycle will recover faster than expected, which is far from certain.

Key Risks

Conclusion

Joel Greenblatt's approach is to buy good companies (high ROC) at cheap prices (high earnings yield). IQE currently offers neither. Its ROC is negative due to operating losses, and even normalized returns are likely mediocre given the capital intensity and competitive dynamics. The earnings yield is non-existent because the company isn't generating earnings, and the price embeds overly optimistic recovery assumptions. A disciplined Magic Formula investor would exclude IQE from consideration. While the company operates in exciting end-markets (AI, defense), it has not demonstrated the ability to produce the consistent high returns on capital that the formula demands. The stock is a speculative turnaround play, not a Magic Formula candidate. Sell.

Overview

A CAN SLIM analysis of IQE plc, a compound semiconductor wafer supplier, using William J. O'Neil's methodology. The report evaluates IQE against all seven CAN SLIM criteria based on provided financial data and recent news, acknowledging a highly speculative turnaround situation.

Financial and Business Overview

IQE develops and manufactures advanced epitaxial wafers for wireless, photonics, and power electronics markets. Revenue for FY2025 (TTM) stands at approximately £97 million, with a return to positive adjusted EBITDA of at least £2 million after a prior-year loss. However, earnings per share remain deeply negative at -0.05 (TTM) and -0.01 forward. The balance sheet has been stressed but was recently strengthened by an £81 million strategic fundraise led by customer MACOM, which includes equity, convertible notes, and long-term supply agreements. Gross debt is £86.8 million against £17 million cash, giving net debt of ~£70 million. The company is undergoing a strategic review (now concluded with the MACOM deal) and has exited non-core assets. The business model is a high-fixed-cost epitaxial foundry; capacity utilisation is critical for profitability.

Market Position & Competitive Advantages

IQE is the world's largest independent compound semiconductor epitaxial wafer foundry, with over 30 years of process know-how, a wide IP portfolio (GaN, InP, GaAs, GaSb), and long qualification cycles that create high switching costs for customers. It supplies critical components for AI data-centre photonics, 5G RF, defence radar, and power electronics. Competitors include Coherent, Wolfspeed, and internal epitaxial capacity at IDMs. IQE's recent deal with MACOM and multi-year supply agreement with Lumentum validate its technology. However, customer concentration (Apple supply chain via Lumentum/Coherent) and the cyclicality of wireless markets pose risks. The company has not demonstrated consistent profitability, and its cost structure remains a headwind in downturns.

Stock Performance

The stock has surged dramatically from a 52-week low of 4.66p to a current price of 38p (as of 2026-05-20), a +190% one-year change. It is trading well above its 50-day (37.72p) and 200-day (15.49p) moving averages, indicating a strong technical breakout. Daily average volume (3-month: 38.5 million shares) is exceptionally high relative to a 979.9 million share float, suggesting heavy accumulation. The stock has experienced extreme volatility (weekly moves >24%) and is still 47.87% below its 52-week high of 72.9p, which may act as resistance. The price action reflects the market pricing in a turnaround and AI photonics theme, but the rally has been parabolic at times, increasing the risk of a sharp pullback.

CAN SLIM Analysis

Key Risks

Conclusion

Under William O'Neil's CAN SLIM system, stocks with negative earnings and declining annual earnings histories are automatically ineligible, regardless of other strengths. IQE fails C (Current Earnings) and A (Annual Earnings) outright. While the N factor is exceptional (AI photonics, defence demand, MACOM deal) and the S, L, I, M factors are supportive, the primary driver of exceptional stock gains — powerful earnings growth — is absent. IQE is a 'story' stock priced for a future recovery that may or may not materialise. O'Neil would advise waiting for a proven earnings inflection and a proper breakout from a sound base before considering purchase. The current chart has extended well above moving averages, and chasing a 190% move in a loss-making company violates risk management principles. Therefore, the rating is SELL for CAN SLIM investors. For speculative traders, it's a high-volatility momentum play, but it does not meet CAN SLIM investment criteria.

Overview

A Warren Buffett-style intrinsic value analysis of IQE plc (IQE.L), a compound semiconductor wafer supplier, evaluating its business quality, economic moat, management, financial strength, and long-term investment merit based on available data and recent developments.

Business Understanding

IQE grows epitaxial wafers for compound semiconductors used in photonics, wireless, and power electronics. The business model is capital‑intensive, highly cyclical, and dependent on a few large customers in complex technology sectors. While the concept of an epiwafer foundry is understandable at a high level, the company’s fortunes are tied to unpredictable defense budgets, smartphone cycles, and the nascent AI infrastructure buildout. This falls outside a simple, predictable circle of competence that a traditional value investor would seek.

Economic Moat Analysis

IQE possesses a narrow technical moat based on decades of process know‑how and customer qualification requirements, but this has not translated into sustainable competitive advantages. The industry is fragmented, customers can vertically integrate or qualify alternative suppliers, and the company has no meaningful pricing power. The moat is thin and eroding: Chinese foundries are scaling, large IDMs capture value downstream, and the company remains chronically unprofitable despite its technological pedigree. No wide or durable moat exists.

Management Quality

Management has overseen a multi‑year period of revenue decline, persistent losses, repeated capital raises, and a strategic review that ultimately ended with a major dilutive fundraise and the cessation of takeover interest. Insider selling has been flagged, and the company has relied on covenant waivers from lenders. The board’s willingness to consider a full sale signals that even management believes the company may be worth more broken up than as a going concern. This track record does not demonstrate shareholder‑oriented capital allocation, and no dividends or buybacks have been returned to owners.

Financial Strength

The company is financially fragile. Trailing twelve‑month revenue fell to £97.27M with negative gross margins (-0.015%) and a net loss of £49.14M. Book value per share is only £0.11, and return on equity is deeply negative. Although the recent £81M fundraise from MACOM and others has repaired the balance sheet temporarily (net debt reduced, cash raised), the underlying business still burns cash and cannot cover its fixed costs at current utilization. Free cash flow has been inconsistent and insufficient. Profit margins are negative and highly volatile. This is not a fortress balance sheet.

Intrinsic Value Assessment

Owner earnings are negative, as net losses far exceed any non‑cash charges. Even on an optimistic recovery scenario, the company would need to roughly double revenue just to break even, and it lacks the pricing power or market position to guarantee that. With a market capitalization of £372M against negative earnings and negligible book value, there is no margin of safety. The current price of 38p implies a speculative bet on a cyclical recovery, a take‑out premium, or a transformation that has eluded the firm for years. A rational intrinsic value is substantially below the current price.

Key Risks

Investment Details